Ocular Therapeutix has presented compelling post-hoc analyses from the SOL-1 Phase 3 trial of AXPAXLI (OTX-TKI) at the 14th Annual Vit-Buckle Society Meeting, underscoring its unmatched durability in managing wet age-related macular degeneration (wet AMD). The analyses reveal that AXPAXLI provides robust control of central subfield thickness (CSFT), with median times of 39 weeks and 46 weeks to significant increases in CSFT compared to aflibercept, indicating a 30% to 50% lower risk of disease progression in the AXPAXLI group.

The data highlights a strong overall efficacy profile with statistical significance across multiple secondary endpoints, including sustained visual acuity gains maintained up to Week 52. Notably, patients in the lowest baseline visual acuity quartile experienced the most significant improvements, with an average gain of +11.8 ETDRS letters. The safety profile remains reassuring, with no significant adverse events and a mean resolution time of 20 weeks for vitreous floaters, aligning with the expected behavior of the hydrogel formulation.

The implications of these findings are profound for the field of retinal therapeutics. The durability and efficacy of AXPAXLI could shift current treatment paradigms, potentially reducing the frequency of intraocular injections and improving patient adherence. With plans to submit a New Drug Application (NDA) based solely on the SOL-1 trial data, Ocular Therapeutix is poised to expedite the clinical adoption of AXPAXLI, potentially reshaping the management landscape for wet AMD if approved. This development aligns with recent FDA commentary indicating a shift toward accepting single pivotal trials for regulatory approval, which may streamline future drug development timelines in this space.

Source: globenewswire.com